LC/MS/MS VS. LC/HRMS: Identifying and quantifying oligonucleotides
LC/MS/MS and LC/HRMS are formidable instruments employed in mass spectrometry for the identification and quantification of Oligonucleotides (OGNTs). Utilizing these approaches, drug developers can obtain detailed insights into the composition and structure of molecules for biotechnology and pharmaceuticals.
Considerations for choosing the right approach for your drug development project will depend on:
- What instrument you have
- Where you want to go
- How much information you want to collect in a single injection
Discover which technique is best for you.
Optimizing small molecule drug development strategies: A step by step approach to a rugged method
Creating a rugged method for the development of small molecule drugs is crucial in the quest for successful therapies. A systematic approach not only guarantees data consistency and reliability but also empowers you to make well-informed decisions, ultimately boosting project efficiency and success.
To help you navigate the complexities and uncertainties that come with advancing small molecules for drug development, we’ve outlined a robust strategy that includes 7 crucial steps.
Download our fact sheet to learn more.
A guide to the advantages and disadvantages of sample preparation for small molecules
Accurate and reliable results in the drug discovery process rely heavily on the pivotal role of sample preparation. By adopting optimized sample preparation techniques, you can significantly improve the quality of your data.
Sample preparation for small molecules involves three primary modes:
- Protein precipitation
- Supported liquid exchange / liquid/liquid extraction
- Solid phase extraction
Our comprehensive guide offers valuable insights associated with preparing small molecule samples for analysis, including advantages and disadvantages of each preparation mode.
Bioanalytical services for animal health
Aliri has more than 18 years of experience providing state-of-the-art animal health regulatory bioanalytical services to support research and development initiatives. With a team of skilled scientists, advanced technologies, and regulatory expertise, we are committed to delivering accurate and reliable data to expedite project timelines and enhance animal health.
Aliri by the numbers:
- 45 animal health clients
- 300+ studies supported
- 70 compounds
- 100+ custom assays
- 150 biological fluids and tissues
Explore our assay experience, platforms, regulations and more:
Oligonucleotides: Where we started, where we stand, and where we would like to go
Oligonucleotides, which are short chains of nucleotides that make up DNA and RNA, are used in a wide range of applications in bioanalysis and play a critical role in understanding the molecular mechanisms of living cells and diseases.
Organic Synthetic Chemist, Troy Voelker PhD, discusses common methods to support the bioanalysis of oligonucleotides (OGNTs) and a future perspective regarding areas for improvement.
His insights explores a range of analytical techniques for OGNTs, including:
-Basics of oligonucleotide bioanalysis
-Selecting an approach
-Methods of extraction
-Handling Hybridization methods
-Goals for future analysis
Discover how future predictions for oligonucleotide bioanalysis will help improve medicine, therapeutics and genetic testing.
RNAscope assay: Single cell transcriptomics for drug target discovery
When dealing with biomarkers in drug target discovery, profiling the tissue transcriptome in its spatial organization is key to understanding and predicting that tissue’s response to immunotherapy, because the tissue function within the body relies on the precise spatial organization of the cells. This is especially true when dealing with complex and heterogeneous tissues, such as tumors.
With tumors, the relationship between the cells and their environment is what ultimately shapes a patient’s fate. Applying the RNAscopeTM assay allows that evaluation of the presence of transcripts within a spatial context. This technique then ultimately can predict the tumor’s response to immunotherapy.
To further explain the impact of the RNAscope assay, this application note details a case study on a non-small-cell lung cancer (NSCLC) sample to predict its response to immunotherapy. This case study:
- Investigates the presence of the PD-L1 drug target transcript and the Granzyme B (GZMB) biomarker of clinical outcome transcript
- Explains quality control measures taken to validate the hybridization technique
Looks at the heterogenous distribution of transcripts in the NSCLC tissue section & examines the quantification of the PD-L` and GZMB to draw conclusions on the tissue’s reaction
Timeline planning tips for importing or exporting biological samples
Missed deadlines in drug development often stem from improper planning and coordination during the import and export of biological samples. Establishing and executing a proper plan for this part of the process can help ensure that your program stays on-track, while avoiding unnecessary stress such as costly delays, lost shipments, etc.
Download this infographic to learn more about this robust process:
- Permits and government agency requirements
- Human vs animal requirements
- Timelines and expectations
- Resources and process planning
QMSI vs. QWBA: evaluating benefits and risks
Knowing when to use Quantitative Mass Spectrometry Imaging (QMSI) instead of Quantitative Whole-Body Autoradiography (QWBA) can make or break a timeline and budget for pharma and biotech companies.
Consider the following key advantages when selecting which technique is right for your drug development program:
QSMI Advantages:
- Label-free quantification of thousands of analytes
- Excellent differentiation among parent drugs, metabolites, and other substances
- Highly specific in quantification by location in tissue
QWBA Advantages:
- Highly precise quantification capabilities, even at low and high limits of detection
- Spatial resolution at the cellular level
- Gold standard technique for the late-stage regulatory distribution studies
Even though QWBA remains the gold standard technique during late stage for regulatory agencies, QMSI is frequently used in support of the autoradiography in certain circumstances.
Further evaluate the benefits and risks associated with each technology.
Buy vs Build: Bioanalytical lab
Buying a bioanalytical lab vs. building one yourself – what do you need to consider?
With so many outsourcing/insourcing options across the drug development workflow, Pharma companies are faced with finding the right partner to fit all the needs of their unique molecule. Here are some criteria to consider:
- Time to Launch: timelines depend on the approach. A built-for-purpose project translates to long timelines due to all the parties involved. You need time to evaluate location, engineers, & architects. Return on investment and risk impact: both are dependent on the number of programs and the diversity of projects. To fully evaluate, you need to build utilization models to analyze and make predictions
- Staffing appropriately: the job market can be challenging to navigate, and it could prove to be challenging to find the right expertise and employees. Be prepared for this process to take time and be costly.
- Day to Day Logistics: there are a wide variety of permits & licenses needed for day-to-day operations. This regulatory environment can be complicated to navigate as you manage the applications, requirements and maintenance required.
If you are interested in learning more about permits & licenses specifically, check out our fact sheet: Guidelines to Importing & Exporting Biological Samples - And much more…
Explore our comprehensive guide that outlines the benefits & risks associated with buying or building a bioanalytical lab and see what choice is best for you.
Guidelines: Importing & Exporting Biological Samples
The United States government has a heavily regulated process for importing and exporting biological samples, and for good reason. These protocols are designed to prevent the transportation of exotic diseases and to inhibit the supply to illegal markets.
While understanding the reasons for the high regulation, it can still be extremely complicated to navigate the different governing bodies and acquire the correct applications or permits. Failure to follow the process also has dire consequences: samples can get held at customs, there may be fines involved, and your estimated drug development timeline just got much longer.
We know how frustrating delays in your development process are. Our comprehensive guide gives you the information you need to be confident that your samples will not be compromised, and your timeline will not be delayed. Download our comprehensive guide to learn how to properly import and export biological samples to avoid potential issues and stay on track.